Pure Global

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults - Trial NCT06420765

Access comprehensive clinical trial information for NCT06420765 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06420765
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06420765
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Effects of Single Doses of NaV1.8 Inhibitors on C-Nociceptor Action Potentials in Healthy Adults

Study Focus

Pain

VX-150

Interventional

drug

Sponsor & Location

Vertex Pharmaceuticals Incorporated

Timeline & Enrollment

Phase 1

May 01, 2024

Sep 01, 2025

40 participants

Primary Outcome

Change From Baseline in Activity Dependent Slowing (ADS) Over Time

Summary

The purpose of this study is to determine the effects of Nav1.8 inhibition on
 activity-dependent slowing (ADS) of C-nociceptor nerve fibers, evoked action potential (AP)
 conduction velocity of C-nociceptor nerve fibers using VX-150 and VX-548.

ICD-10 Classifications

Pain, unspecified
Pain, not elsewhere classified
Pain in limb
Acute pain
Other chronic pain

Data Source

ClinicalTrials.gov

NCT06420765

Non-Device Trial